Anti-PD-L1 antibody administration prevented sepsis-induced depletion of lymphocytes, increased tumor necrosis factor (TNF)-α and interleukin (IL)-6 productions, decreased IL-10 production, and enhanced bacterial clearance. This evidence concerns the gene IL6 and Sepsis.